Innate Pharma S.A. ADS (IPHA)
NASDAQ: IPHAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
IPHA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $96.44M
- EPS (TTM)
- -$0.59
- Dividend yield
- None
- 52-week range
- 0.829 – 2.71
- Day range
- 0.829 – 0.9084
- Volume / Avg
- 18.03K / 42.76K
- Beta
- —
- Shares outstanding
- 111.70M
52-week range
IPHA stock today
Innate Pharma S.A. (IPHA) closed at $0.8634 on Nov 20, down 8.14% (-$0.0765), versus the S&P 500's 3.70% decline. Trading was light, with 18.03K shares changing hands, about 42% of the average daily volume. At this level, IPHA sits near the bottom of its 52-week range of $0.829 to $2.71: 68.1% below the high, set on Aug 13, 2026 and 4.1% above the low.
IPHA is down 50.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 52.6%. Innate Pharma S.A. has posted a net loss over the last twelve months (EPS of -$0.59), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Innate Pharma S.A.
Company profileInnate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Jonathan E. Dickinson B.Sc., M.B.A.
- Headquarters
- Marseille
- Employees
- 120
- IPO year
- 2019
- Website
- innate-pharma.com
Analyst forecast
ForecastConsensus (3 analysts)
buy
Avg. price target
$8.00+826.57%
- Strong buy 0
- Buy 2
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
IPHA news
All IPHA news- Innate Pharma S.A. Presents Initial Phase 1 Clinical Data for IPH4502Nasdaq
- Innate Pharma S.A. to Host Event on IPH4502 on November 18, 2026Nasdaq
- Innate Pharma Reports Third Quarter 2026 Business and Financial UpdateBusiness Wire
- Innate Pharma S.A. Announces PACIFIC-9 Phase 3 Trial Readout Timing Updated to H1 2027Nasdaq
Innate Pharma S.A. peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| MOLNMolecular Partners AG ADR | 2.53 | -5.25% | $96.80M | vs IPHA |
| VYGRVoyager Therapeutics Inc. | 1.53 | -4.97% | $95.21M | vs IPHA |
| OTLKOutlook Therapeutics Inc. | 0.39 | -2.74% | $94.94M | vs IPHA |
| LENZLENZ Therapeutics Inc. | 2.97 | -11.23% | $93.16M | vs IPHA |
| ZURAZura Bio Limited Class A | 0.9305 | -2.30% | $89.63M | vs IPHA |
| CRDLCardiol Therapeutics Inc. Class A | 0.8626 | -2.28% | $110.14M | vs IPHA |
| FATEFate Therapeutics Inc. | 0.919 | -9.01% | $111.82M | vs IPHA |
| ARMPArmata Pharmaceuticals Inc. | 3.03 | +1.68% | $112.69M | vs IPHA |
Indexes, lists and sector
Innate Pharma S.A. stock FAQ
What is Innate Pharma S.A.'s stock price today?
IPHA last traded at $0.8634 as of Nov 20, 4:00 PM EST, down 8.14% on the day. Prices are delayed at least 15 minutes.
Who is Innate Pharma S.A.'s CEO?
Mr. Jonathan E. Dickinson B.Sc., M.B.A. is the chief executive officer of Innate Pharma S.A. ADS, which has about 120 employees.
What is the IPHA 52-week high?
The 52-week high for IPHA is $2.71 and the 52-week low is $0.829. The stock is currently 68.1% below its high.